Lundbeck reports solid sales growth in Europe  

2006.05.11
Danish pharmaceutical company Lundbeck's Q1 2006 report shows a 56% rise in European sales of its antidepressant drug Cipralex

Danish pharmaceutical company Lundbeck's Q1 2006 report shows a 56% rise in European sales of its antidepressant drug Cipralex. Lundbeck's introduction of Cipralex in France has been the most successful launch of the product in any European country with a market share of 7.1% after only nine months. In Germany sales are also progressing steadily, although comprehensive health reforms in the country have not yet reached the market for antidepressants.

Claus Bræstrup, CEO of Lundbeck comments: "France is a significant element, but it is important to emphasise that we are talking about progress on a broad European front. When you look into the figures, Cipralex and Ebixa [a product for the treatment of Alzheimer's disease – Ed] are doing well in the parts of the world where we are responsible for sales. The strong growth of Cipralex and Ebixa gives Europe a more prominent position in our business. And we are happy about that."

Lundbeck's European activities account for 61% of total Q1 revenues of DKK 2.2 bn (USD 374 m) compared to 53% by the end of Q4 2005. The news was reported by national daily newspaper Berlingske Tidende.

Lundbeck is an international pharmaceutical company engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2005, the company generated revenues of DKK 9.1 bn (USD 1.5 bn). Lundbeck is headquartered in Copenhagen and employs approx. 5,000 people.

Link > Lundbeck 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×